Profile data is unavailable for this security.
About the company
Wave Life Sciences Ltd. is a biotechnology company. The Company is focused on unlocking the potential of RNA medicines (oligonucleotides), or those targeting ribonucleic acid (RNA), to transform human health. Its RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing and RNA interference (RNAi), providing Company with capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. These programs include WVE-N531, WVE-006 and WVE-003. It is also building a pipeline of novel A-to-I RNA editing oligonucleotides (AIMers).
- Revenue in USD (TTM)113.31m
- Net income in USD-57.51m
- Incorporated2012
- Employees266.00
- LocationWAVE Life Sciences Ltd7 Straits View#12-00, Marina One East Tower 018936SingaporeSGP
- Phone+65 62363388
- Websitehttps://www.wavelifesciences.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Korro Bio Inc | 0.00 | -59.32m | 709.25m | 48.00 | -- | 1.78 | -- | -- | -83.09 | -83.09 | 0.00 | 49.74 | 0.00 | -- | -- | 0.00 | -65.05 | -29.26 | -77.66 | -34.01 | -- | -- | -- | -288.37 | -- | -- | 0.00 | -- | -100.00 | -- | 3.67 | -- | -- | -- |
Nurix Therapeutics Inc | 76.99m | -143.95m | 710.92m | 284.00 | -- | 3.53 | -- | 9.23 | -2.65 | -2.65 | 1.42 | 4.12 | 0.1994 | -- | -- | 271,081.00 | -37.27 | -33.01 | -46.83 | -39.66 | -- | -- | -186.98 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
Northwest Biotherapeutics Inc | 1.93m | -64.37m | 713.98m | 25.00 | -- | -- | -- | 369.56 | -0.0573 | -0.0573 | 0.0017 | -0.04 | 0.0653 | -- | -- | 77,280.00 | -211.53 | -381.58 | -- | -- | -- | -- | -3,240.11 | -6,479.25 | -- | -- | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
Y-mAbs Therapeutics Inc | 84.82m | -21.43m | 722.32m | 100.00 | -- | 7.14 | -- | 8.52 | -0.4909 | -0.4909 | 1.94 | 2.31 | 0.6299 | 1.93 | 4.85 | 848,190.00 | -15.91 | -44.23 | -19.40 | -50.45 | 86.60 | -- | -25.26 | -181.13 | 5.27 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
Aurinia Pharmaceuticals Inc | 175.51m | -78.02m | 723.09m | 300.00 | -- | 1.90 | -- | 4.12 | -0.5454 | -0.5454 | 1.23 | 2.63 | 0.3445 | 0.439 | 9.34 | 585,043.30 | -15.31 | -25.97 | -17.42 | -28.24 | 91.94 | -- | -44.45 | -137.64 | 4.99 | -- | 0.1925 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
Applied Therapeutics Inc | 9.99m | -119.76m | 725.32m | 25.00 | -- | -- | -- | 72.58 | -1.42 | -1.42 | 0.1288 | -0.202 | 0.2145 | -- | -- | 399,720.00 | -257.01 | -140.37 | -- | -240.93 | -- | -- | -1,198.47 | -4,476.42 | -- | -- | -- | -- | -- | -- | -45.15 | -- | -- | -- |
Zymeworks Inc | 76.01m | -118.67m | 726.85m | 272.00 | -- | 1.57 | -- | 9.56 | -1.74 | -1.74 | 1.10 | 6.57 | 0.1236 | -- | 2.88 | 279,455.90 | -19.30 | -22.58 | -22.01 | -26.90 | -- | -- | -156.13 | -91.17 | -- | -- | 0.0003 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
Exscientia PLC (ADR) | 30.92m | -181.88m | 728.97m | 481.00 | -- | 1.45 | -- | 23.58 | -1.46 | -1.46 | 0.2484 | 3.98 | 0.04 | -- | 2.40 | 64,272.87 | -23.54 | -- | -26.71 | -- | -26.74 | -- | -588.31 | -- | -- | -- | 0.0445 | -- | -0.4971 | -- | -141.17 | -- | -- | -- |
Wave Life Sciences Ltd | 113.31m | -57.51m | 738.60m | 266.00 | -- | 18.16 | -- | 6.52 | -0.5397 | -0.5397 | 1.07 | 0.3987 | 0.5378 | -- | -- | 425,958.70 | -27.30 | -56.98 | -70.41 | -102.38 | -- | -- | -50.76 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
OPKO Health Inc | 863.49m | -188.86m | 745.78m | 3.93k | -- | 0.5956 | -- | 0.8637 | -0.2513 | -0.2513 | 1.15 | 1.80 | 0.4133 | 7.80 | 6.89 | 219,718.60 | -9.03 | -7.14 | -10.03 | -8.14 | 36.84 | 34.42 | -21.86 | -13.83 | 1.22 | -15.24 | 0.1574 | -- | -14.01 | -2.70 | 42.49 | -- | -10.19 | -- |
Astria Therapeutics Inc | 0.00 | -72.89m | 746.68m | 59.00 | -- | 3.78 | -- | -- | -2.34 | -2.34 | 0.00 | 5.92 | 0.00 | -- | -- | 0.00 | -30.04 | -64.48 | -31.37 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
enGene Holdings Inc | 0.00 | -106.80m | 751.34m | 33.00 | -- | 6.41 | -- | -- | -4.60 | -4.60 | 0.00 | 2.69 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.37 | 0.2653 | -- | -- | -- | -260.87 | -- | -- | -- |
Allogene Therapeutics Inc | 95.00k | -327.27m | 754.15m | 232.00 | -- | 1.47 | -- | 7,938.42 | -2.09 | -2.09 | 0.0006 | 3.04 | 0.0001 | -- | -- | 409.48 | -44.70 | -28.46 | -47.65 | -30.21 | -- | -- | -344,489.50 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
Longboard Pharmaceuticals Inc | 0.00 | -54.42m | 755.64m | 50.00 | -- | 12.57 | -- | -- | -2.39 | -2.39 | 0.00 | 1.67 | 0.00 | -- | -- | 0.00 | -89.72 | -- | -105.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
Cullinan Oncology Inc | 0.00 | -153.16m | 763.55m | 85.00 | -- | 1.68 | -- | -- | -3.70 | -3.70 | 0.00 | 10.58 | 0.00 | -- | -- | 0.00 | -29.68 | -12.37 | -31.19 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
Holder | Shares | % Held |
---|---|---|
RA Capital Management LPas of 31 Dec 2023 | 18.20m | 15.29% |
Maverick Capital Ltd.as of 31 Dec 2023 | 8.45m | 7.10% |
M28 Capital Management LPas of 31 Dec 2023 | 7.37m | 6.20% |
Adage Capital Management LPas of 31 Dec 2023 | 5.99m | 5.03% |
683 Capital Management LLCas of 31 Dec 2023 | 5.60m | 4.71% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 4.90m | 4.12% |
Bellevue Asset Management AGas of 31 Dec 2023 | 4.49m | 3.78% |
Kynam Capital Management LPas of 31 Dec 2023 | 3.93m | 3.30% |
PRIMECAP Management Co.as of 31 Dec 2023 | 3.76m | 3.16% |
Point72 Asset Management LPas of 31 Dec 2023 | 3.21m | 2.70% |